MediWound (NASDAQ:MDWD) Share Price Passes Above 50 Day Moving Average - Here's What Happened

MediWound Ltd. (NASDAQ:MDWD - Get Free Report)'s share price passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $17.41 and traded as high as $20.67. MediWound shares last traded at $19.89, with a volume of 83,831 shares changing hands.

Analysts Set New Price Targets

Several equities analysts have commented on MDWD shares. Alliance Global Partners started coverage on MediWound in a research report on Friday, May 2nd. They issued a "buy" rating and a $25.00 price objective on the stock. HC Wainwright set a $31.00 target price on MediWound and gave the stock a "buy" rating in a report on Thursday, May 22nd. Wall Street Zen upgraded MediWound to a "sell" rating in a report on Friday, March 21st. Finally, Craig Hallum assumed coverage on MediWound in a report on Friday, February 28th. They issued a "buy" rating and a $39.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $31.25.

MediWound Stock Performance

The firm has a market capitalization of $229.40 million, a PE ratio of -7.32 and a beta of 0.30. The company has a fifty day simple moving average of $17.50 and a two-hundred day simple moving average of $17.65.

MediWound (NASDAQ:MDWD - Get Free Report) last issued its earnings results on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.58. The business had revenue of $3.96 million during the quarter, compared to analysts' expectations of $5.20 million. MediWound had a negative return on equity of 82.17% and a negative net margin of 142.29%. During the same period in the prior year, the business earned ($1.05) EPS. On average, equities analysts anticipate that MediWound Ltd. will post -2.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MediWound

A number of hedge funds have recently made changes to their positions in the stock. Yelin Lapidot Holdings Management Ltd. lifted its stake in shares of MediWound by 0.8% during the 1st quarter. Yelin Lapidot Holdings Management Ltd. now owns 858,000 shares of the biopharmaceutical company's stock worth $13,316,000 after purchasing an additional 6,639 shares during the last quarter. Essex Investment Management Co. LLC lifted its stake in shares of MediWound by 30.7% during the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company's stock worth $2,651,000 after purchasing an additional 35,012 shares during the last quarter. Northern Trust Corp lifted its stake in shares of MediWound by 94.6% during the 4th quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company's stock worth $2,577,000 after purchasing an additional 70,367 shares during the last quarter. Sargent Investment Group LLC lifted its stake in shares of MediWound by 3.4% during the 4th quarter. Sargent Investment Group LLC now owns 121,190 shares of the biopharmaceutical company's stock worth $2,217,000 after purchasing an additional 3,998 shares during the last quarter. Finally, ARK Investment Management LLC lifted its stake in shares of MediWound by 6.7% during the 1st quarter. ARK Investment Management LLC now owns 106,930 shares of the biopharmaceutical company's stock worth $1,660,000 after purchasing an additional 6,684 shares during the last quarter. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.